Stentys has started to enrol patients in its TRUNC trial, which is designed to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main coronary artery disease. The first implantation was performed at Treant hospital in Emmen, the Netherlands, with operators Rutger Anthonio and Gillian Jessurun commenting that the procedure went “very smoothly”.
The TRUNC is a prospective, single-arm multicentre trial that aims to evaluate the long-term safety and efficacy of the Xposition S stent in the treatment of unprotected left main lesions in routine clinical practice. It is scheduled to include 200 patients in approximately 20 European clinical sites. The primary endpoint is target lesion fFailure at 12 months. The trial’s steering committee is composed of Corrado Tamburino, Carlo Briguori, and Andreas Baumbach.
Rutger Anthonio and Gillian Jessurun—both Treant hospital (Emmen, The Netherlands), where the first implantation was performed—comment: “The procedure went very smoothly. The Xposition S stent is perfectly suited for the treatment of left main lesions, because it guarantees excellent apposition in a vessel segment with substantial diameter variation. In addition, the stent allows easy access to any anatomical side branch without the need to perform kissing balloon inflation, which minimises overall manipulation.”
